Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn’s Disease

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. The Lancet. 2017;390(10114):2769–2778. doi:10.1016/S0140-6736(17)32448-0
   PubMed Web of Science ®Google Scholar
• Mak WY, Mak OS, Lee CK, et al. Significant medical and surgical morbidity in perianal crohn’s disease: results from a territory-wide study. J Crohns Colitis. 2018;12:1392–1398. doi:10.1093/ecco-jcc/jjx180.915
   PubMed Web of Science ®Google Scholar
• Bouguen G, Siproudhis L, Gizard E, et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(975–81):e1–4. doi:10.1016/j.cgh.2012.12.042
   PubMed Web of Science ®Google Scholar
• Lee JB, Yoon SG, Park KJ, et al. The clinical features and predictive risk factors for reoperation in patients with perianal crohn diseases; a multi-center study of a korean inflammatory bowel disease study group. Ann Coloproctol. 2015;31:176–181. doi:10.3393/ac.2015.31.5.176
   PubMedGoogle Scholar
• Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-Year follow-up study of the natural history of perianal Crohn’s Disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25:1227–1236. doi:10.1093/ibd/izy374
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn’s disease. Gastroenterology. 2003;125:1508–1530. doi:10.1016/j.gastro.2003.08.025
   PubMed Web of Science ®Google Scholar
• Kotze PG, Shen B, Lightner A, et al. Modern management of perianal fistulas in Crohn’s disease: future directions. Gut. 2018;67:1181–1194. doi:10.1136/gutjnl-2017-314918
   PubMed Web of Science ®Google Scholar
• Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–1392. doi:10.1136/gutjnl-2013-306709
   PubMed Web of Science ®Google Scholar
• Herissay A, Siproudhis L, Le Balc’h E, et al. Combined strategies following surgical drainage for perianal fistulizing Crohn’s disease: failure rates and prognostic factors. Colorectal Dis. 2020. 23(1):159–168.
   PubMed Web of Science ®Google Scholar
• Park SH, Aniwan S, Scott Harmsen W, et al. Update on the natural course of fistulizing perianal Crohn’s disease in a population-based cohort. Inflamm Bowel Dis. 2019;25:1054–1060. doi:10.1093/ibd/izy329
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–1405. doi:10.1056/NEJM199905063401804
   PubMed Web of Science ®Google Scholar
• Laharie D, Mesli S, El Hajbi F, et al. Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study. Aliment Pharmacol Ther. 2011;34(4):462–469. doi:10.1111/j.1365-2036.2011.04743.x
   PubMed Web of Science ®Google Scholar
• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–59,quiz 660. doi:10.1038/ajg.2011.73
   PubMed Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.e5;quiz e31.
   Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70e5; quiz e31. doi:10.1053/j.gastro.2011.09.034
   Web of Science ®Google Scholar
• Chhaya V, Saxena S, Cecil E, et al. Emerging trends and risk factors for perianal surgery in Crohn’s disease: a 20-year national population-based cohort study. Eur J Gastroenterol Hepatol. 2016;28:890–895. doi:10.1097/MEG.0000000000000651
   PubMed Web of Science ®Google Scholar
• Malian A, Riviere P, Bouchard D, et al. Pedictors of perianal fistula relapse in Crohn’s disease. Inflamm Bowel Dis. 2020;26:926–931. doi:10.1093/ibd/izz200
   PubMed Web of Science ®Google Scholar
• Gomollon F, Dignass A, Annese V 3rd, et al. European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25. doi:10.1093/ecco-jcc/jjw168
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1–s106.
   PubMed Web of Science ®Google Scholar
• Kochar B, Barnes EL, Herfarth HH, et al. Asians have more perianal Crohn disease and ocular manifestations compared with white Americans. Inflamm Intest Dis. 2018;2:147–153. doi:10.1159/000484347
   PubMedGoogle Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–885. doi:10.1056/NEJMoa030815
   PubMed Web of Science ®Google Scholar
• Sun XL, Chen SY, Tao SS, et al. Optimized timing of using infliximab in perianal fistulizing Crohn’s disease. World J Gastroenterol. 2020;26:1554–1563. doi:10.3748/wjg.v26.i14.1554
   PubMed Web of Science ®Google Scholar
• Legue C, Brochard C, Bessi G, et al. Outcomes of perianal fistulising crohn’s disease following Anti-TNFalpha treatment discontinuation. Inflamm Bowel Dis. 2018;24:1107–1113. doi:10.1093/ibd/izy008
   PubMed Web of Science ®Google Scholar
• Vuyyuru SK, Sahu P, Kedia S, et al. Long-term outcomes in perianal fistulizing Crohn’s disease in a resource-limited setting: a cohort analysis. Indian J Gastroenterol. 2020;39:435–444. doi:10.1007/s12664-020-01054-7
   PubMed Web of Science ®Google Scholar
• Wasmann KA, de Groof EJ, Stellingwerf ME, et al. Treatment of perianal fistulas in Crohn’s Disease, Seton versus anti-TNF versus surgical closure following Anti-TNF [PISA]: a randomised controlled trial. J Crohns Colitis. 2020;14(8):1049–1056. doi:10.1093/ecco-jcc/jjaa004
   PubMed Web of Science ®Google Scholar
• Adler J, Lin CC, Gadepalli SK, et al. Association between steroid-sparing therapy and the risk of perianal fistulizing complications among young patients with Crohn disease. JAMA Netw Open. 2020;3(6):e207378. doi:10.1001/jamanetworkopen.2020.7378
   PubMed Web of Science ®Google Scholar
• Sebastian S, Black C, Pugliese D, et al. The role of multimodal treatment in Crohn’s disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018;48:941–950. doi:10.1111/apt.14969
   PubMed Web of Science ®Google Scholar
• El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas. Colorectal Dis. 2012;14(10):1217–1223. doi:10.1111/j.1463-1318.2012.02944.x
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Loftus EV Jr., Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–880. doi:10.1053/gast.2002.32362
   PubMed Web of Science ®Google Scholar
• Hyder SA, Travis SP, Jewell DP, et al. Fistulating anal Crohn’s disease: results of combined surgical and infliximab treatment. Dis Colon Rectum. 2006;49:1837–1841. doi:10.1007/s10350-006-0656-5
   PubMed Web of Science ®Google Scholar
• Bor R, Farkas K, Balint A, et al. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn’s disease--clinical observations from a tertiary Eastern European center. Scand J Gastroenterol. 2015;50:182–187. doi:10.3109/00365521.2014.936033
   PubMed Web of Science ®Google Scholar
• Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn’s Disease: surgical treatment. J Crohns Colitis. 2020;14:155–168. doi:10.1093/ecco-jcc/jjz187
   PubMed Web of Science ®Google Scholar
• Bell SJ, Williams AB, Wiesel P, et al. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1145–1151. doi:10.1046/j.1365-2036.2003.01561.x
   PubMed Web of Science ®Google Scholar
• Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol. 2006;4:1130–1134. doi:10.1016/j.cgh.2006.06.021
   PubMed Web of Science ®Google Scholar
• Hirten RP, Shah S, Sachar DB, et al. The management of intestinal penetrating Crohn’s disease. Inflamm Bowel Dis. 2018;24:752–765. doi:10.1093/ibd/izx108
   PubMed Web of Science ®Google Scholar
• Mak JWY, Tang W, Yip TCF, et al. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn’s disease. Aliment Pharmacol Ther. 2019;50:1195–1203. doi:10.1111/apt.15547
   PubMed Web of Science ®Google Scholar
• Roumeguere P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn’s disease: results from a prospective study. Inflamm Bowel Dis. 2011;17:69–76. doi:10.1002/ibd.21405
   PubMed Web of Science ®Google Scholar
• Tozer P, Ng SC, Siddiqui MR, et al. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for crohn’s perianal fistulas. Inflamm Bowel Dis. 2012;18:1825–1834. doi:10.1002/ibd.21940
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus. Inflamm Bowel Dis. 2019;25:1–13. doi:10.1093/ibd/izy247
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A, et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am J Gastroenterol. 2009;104:2973–2986. doi:10.1038/ajg.2009.509
   PubMed Web of Science ®Google Scholar
• Plevris N, Jenkinson PW, Arnott ID, et al. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn’s disease. Eur J Gastroenterol Hepatol. 2020;32:32–37. doi:10.1097/MEG.0000000000001561
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45:933–940. doi:10.1111/apt.13970
   PubMed Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis. 2017;11:549–555.
   PubMed Web of Science ®Google Scholar
• Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP consensus on surgery for Crohn’s Disease. J Crohns Colitis. 2018;12:1–16.
   PubMed Web of Science ®Google Scholar